Forest Expects Multiple Celexa Generics To Enter Market In January
This article was originally published in The Pink Sheet Daily
Executive Summary
Company sees "no impediments" to ANDA approvals for antidepressant, beyond demands on FDA resources to review multiple applications simultaneously. Forest believes the agency will try to approve all generics simultaneously, making it difficult to complete the reviews before the end of the year.
You may also be interested in...
Alphapharm's Attempt To Force Listing of Celexa Patent Rejected By Court
Federal judge affirms FDA's "ministerial" role in declining to list certain patents in the "Orange Book." Forest said the patent should not be listed because it claims an intermediate of citalopram.
Alphapharm's Attempt To Force Listing of Celexa Patent Rejected By Court
Federal judge affirms FDA's "ministerial" role in declining to list certain patents in the "Orange Book." Forest said the patent should not be listed because it claims an intermediate of citalopram.
Lexapro SSRI Switch Plan On Target Despite Slower Than Expected Decline In Celexa Sales
Forest attributes the majority of Celexa’s $15.4 mil. sequential quarterly sales growth to a 4% price increase taken in March. Forest’s estimates put the Celexa revenue run rate in early 2005 at $680 mil., above earlier predictions.